1. Home
  2. CRSP vs MGRC Comparison

CRSP vs MGRC Comparison

Compare CRSP & MGRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • MGRC
  • Stock Information
  • Founded
  • CRSP 2013
  • MGRC 1979
  • Country
  • CRSP Switzerland
  • MGRC United States
  • Employees
  • CRSP N/A
  • MGRC N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • MGRC Diversified Commercial Services
  • Sector
  • CRSP Health Care
  • MGRC Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • MGRC Nasdaq
  • Market Cap
  • CRSP 3.3B
  • MGRC 2.8B
  • IPO Year
  • CRSP 2016
  • MGRC N/A
  • Fundamental
  • Price
  • CRSP $44.25
  • MGRC $111.73
  • Analyst Decision
  • CRSP Buy
  • MGRC Buy
  • Analyst Count
  • CRSP 15
  • MGRC 2
  • Target Price
  • CRSP $70.62
  • MGRC $145.50
  • AVG Volume (30 Days)
  • CRSP 2.5M
  • MGRC 134.7K
  • Earning Date
  • CRSP 08-04-2025
  • MGRC 07-24-2025
  • Dividend Yield
  • CRSP N/A
  • MGRC 1.74%
  • EPS Growth
  • CRSP N/A
  • MGRC 88.16
  • EPS
  • CRSP N/A
  • MGRC 9.65
  • Revenue
  • CRSP $37,675,000.00
  • MGRC $918,531,000.00
  • Revenue This Year
  • CRSP $30.25
  • MGRC $6.11
  • Revenue Next Year
  • CRSP $268.62
  • MGRC $5.52
  • P/E Ratio
  • CRSP N/A
  • MGRC $11.58
  • Revenue Growth
  • CRSP N/A
  • MGRC 7.31
  • 52 Week Low
  • CRSP $30.04
  • MGRC $95.50
  • 52 Week High
  • CRSP $63.68
  • MGRC $129.93
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 68.22
  • MGRC 49.24
  • Support Level
  • CRSP $42.17
  • MGRC $111.40
  • Resistance Level
  • CRSP $47.04
  • MGRC $118.53
  • Average True Range (ATR)
  • CRSP 2.30
  • MGRC 2.56
  • MACD
  • CRSP 0.47
  • MGRC -0.43
  • Stochastic Oscillator
  • CRSP 74.56
  • MGRC 28.12

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About MGRC McGrath RentCorp

McGrath RentCorp is a rental company. It is comprised of four reportable business segments namely Modular building segment (Mobile Modular); Portable storage container segment (Portable Storage); Electronic test equipment segment (TRS-RenTelco); and its classroom manufacturing business selling modular buildings used primarily as classrooms in California (Enviroplex). The company generates its revenues majorily from the rental of its equipment on operating leases with sales of equipment occurring in the normal course of business.

Share on Social Networks: